Skip to content
Screener

ARS Pharmaceuticals, Inc. SPRY Q1 2025 earnings

Reported May 14, 2025 · Before market open

Revenue$8.0MMiss by $6.7M
EPS-$0.35In line
Revenue estimate$14.7M
EPS estimate-$0.35

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$42.8M
EPS estimate-$0.33

Financials

Q1 2025

Income statement

See full
Revenue$8.0M—
Operating income-$37.2M-182%
Net income-$33.9M-230%
EPS (diluted)-$0.35-218%

Balance sheet

See full
Cash & equivalents$39.9M-28.8%
Total debt$73.0K-66.4%
Total equity$229.0M+2.3%
Total assets$327.3M+43.8%

Cash flow

See full
Operating cash flow-$40.7M-507%
CapEx$91.0K+9.6%
Free cash flow-$40.8M-501%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$1.23B+25.3%
Enterprise value$1.19B+28.5%
P/S12.7×-98,523×

Profitability

See full
Net margin-16.1%-8.1pp
FCF margin-21.7%-10.8pp

Returns & leverage

See full
Return on equity-6.9%-2.8pp
Debt / equity0×0.0×
Current ratio11×-49.9×

Segments

By product

See full
Revenue Under Collaboration Agreements$210.0K—
Revenue Under Supply Agreements-—

By geography

See full
Non Us--100%

FAQ

When did ARS Pharmaceuticals, Inc. report Q1 2025 earnings?
ARS Pharmaceuticals, Inc. (SPRY) reported Q1 2025 earnings on May 14, 2025 before market open.
What were ARS Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
ARS Pharmaceuticals, Inc. reported revenue of $8.0M and eps of $-0.35 for Q1 2025.
Did ARS Pharmaceuticals, Inc. beat estimates in Q1 2025?
Revenue missed the consensus estimate of $14.7M by $6.7M. EPS beat the consensus estimate of $-0.35 by $0.00.
How did ARS Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 218.2% from $-0.11.
Where can I find ARS Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-070899) and the 10-Q periodic report (0000950170-25-070900) directly on SEC EDGAR. The filing index links above go to sec.gov.